|
1. Department of Health, Executive Yuan, Taiwan, R.O.C. Analysis of main causes of death in Taiwan for the Year 2002. pp1-41, 2002. 2. Andriani F, Conte D, Mastrangelo T, Leon M, Ratcliffe C, Roz L, Pelosi G, Goldstraw P, Sozzi G, Pastorino U. Detecting lung cancer in plasma with the use of multiple genetic markers. Int J Cancer. 108: 91-96, 2004. 3. National Health Research Institutes, The common consensus of treating lung cancer. pp1-23, 1998. 4. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr., Gansler TS, Holland JF, Frei III E. Cancer Medicine. Hamilton (Canada): BC Decker Inc; 6th ed, 2003. 5. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR, Bernatz PE, Payne WS, Pairolero PC, Bergstralh EJ. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer. 67:1155-1164, 1991. 6. The web site of Cancer Information Service (CIS), The Cancer Information Service is a source for the latest, most accurate cancer information from the National Cancer Institute (NCI). URL http://cis.nci.nih.gov 7. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA, Tavecchio L. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61: 4675-4678, 2001. 8. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 21: 3902-3908, 2003. 9. Que CM. The assessment of microsatellite alterations in the plasma DNA as biomarkers for the detection of micrometastasis of cancers. A master thesis of the department of Biology in National Changhua University of Education. pp.1-56, 2002. 10. Llanes L, Paez A, Ferruelo A, Lujan M, Romero I, Berenguer A. Detecting circulating prostate cells in patients with clinically localized prostate cancer: clinical implications for molecular staging. BJU Int. 86: 1023-1027, 2000. 11. Laribi A, Berteau P, Luc-Gala J, Eschwege P, Benoit G, Tombal B, Schmitt F, Loric S. Blood-borne RT-PCR assay for prostasin-specific transcripts to identify circulating prostate cells in cancer patients. Eur Urol. 39: 65-71, 2000. 12. Brownbridge GG, Gold J, Edward M, Mackie RM. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol. 144: 279-287, 2001. 13. Kulik J, Nowecki ZI, Rutkowski P, Ruka W, Rochowska M, Skurzak H, Siedlecki JA. Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay. Melanoma Res. 11: 65-73, 2001. 14. Hasselmann DO, Rappl G, Rossler M, Ugurel S, Tilgen W, Reinhold U. Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol Rep. 8:115-118, 2001. 15. Zarghami N, Diamandis EP. Detection of prostate-specific antigen mRNA and protein in breast tumors. Clin Chem. 42: 361-366, 1996. 16. Zarghami N, Levesque M, D’Costa M, Angelopoulou K, Diamandis EP. Frequency of expression of prostate-specific antigen mRNA in lung tumors. Am J Clin Pathol. 108: 184-189, 1997. 17. Lintula S, Stenman UH. The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol. 157: 1969-1972, 1997. 18. Millon R, Jacqmin D, Muller D, Guillot J, Eber M, Abecassis J. Detection of prostrate-specific antigen or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: Clinical implications. Eur Urol. 36: 278-285, 1999. 19. Dingermans AM, Brakenhoff RH, Postmus PE, Giaccone G. Detection of cytokeratin-19 transcripts by reverse transcriptase-polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients. Lab Invest. 77: 213-220, 1997. 20. Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol. 16: 2632-2640, 1998. 21. Jung R, Kruger W, Hosch S, Holweg M, Kroger N, Gutensohn K Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br J Cancer. 78: 1194-1198, 1998. 22. Peck K, Sher YP, Shih JY, Roffler SR, Wu CW, Yang PC. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res. 58: 2761-2765, 1998. 23. Wong CK and Lo YM. Cell-free DNA and RNA in plasma as new tools for molecular diagnostics. Expert Rev Mol Diagn. 3: 785-797, 2003. 24. Leon SA, Shapiro B, Sklaroff DM, and Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37: 646-650, 1977. 25. Anker P, Lyautey J, Lederrey C, and Stroun M. Circulating nucleic acids in plasma or serum. Clin. Chim. Acta 313: 143-146, 2001. 26. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, and Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patient. Oncology. 46: 318-322, 1989. 27. Shiseki M, Kohno T, Adachi J, Okazaki T, Otsuka T, Mizoguchi H, Noguchi M, Hirohashi S and Yokota J. Comparative allelotype of early and advanced stage non-small cell lung carcinomas. Genes Chromosom Cancer. 17: 71-77, 1997. 28. Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, Minna JD, and Gazdar AF. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosom Cancer. 21: 308-319, 1998. 29. Strachan T, and Read AP. Human molecular genetics. BIOS scientific publishers Ltd. pp458, 1996. 30. Thiagalingam S, Foy RL, Cheng KH, Lee HJ, Thiagalingam A, and Ponte JF. Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Curr. Opin. Oncol. 14: 65-72, 2002. 31. Devilee P, Cleton-Jansen AM, and Cornelisse CJ. Ever since Knudson. Trends Genet. 17: 569-573, 2001. 32. Oda S, Maehara Y, Ikeda Y, Oki E, Egashira A, Okamura Y, Takahashi I, Kakeji Y, Sumiyoshi Y, Miyashita K, Yamada Y, Zhao Y, Hattori H, Taguchi K, Ikeuchi T, Tsuzuki T, Sekiguchi M, Karran P, Yoshida MA. Two modes of microsatellite instability in human cancer: differential connection of defective DNA mismatch repair to dinucleotide repeat instability. Nucleic Acids Res. 33: 1628-1636, 2005. 33. Atkin NB. Microsatellite instability. Cytogenet. Cell Genet. 92: 177-181, 2001. 34. Girard L, Zöchbauer-Müller S, Virmani AK, Gazdar AF, and Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 60: 4894-4906, 2000. 35. Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, Minna JD, and Gazdar AF. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosom Cancer. 21: 308-319, 1998. 36. Kawanishi M, Kohno T, Otsuka T, Adachi J, Sone S, Noguchi M, Hirohashi S, and Yokota J. Allelotype and replication error phenotype of small cell lung carcinoma. Carcinogenesis. 18: 2057-2062, 1997. 37. Kohno T and Yokota J. How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis. 20: 1403-1410, 1999. 38. Testa JR, Liu Z, Feder M, Bell DW, Balsara B, Cheng JQ, and Taguchi T. Advanced in the analysis of chromosome alterations in human lung carcinomas. Cancer Genet. Cytogenet. 95: 20-32, 1997. 39. Bruhn N, Beinert T, Oehm C, Jandrig B, Petersen I, Chen XQ, Possinger K, Fleischhacker M. Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer. Ann N Y Acad Sci. 906: 72-82, 2000. 40. Tsay JM. The assessment of microsatellite alterations in the plasma DNA as biomarkers for the detection of high risk groups and micrometastasis of hepatocellular carcinomas. A master thesis of the department of Biology in National Changhua University of Education. pp.1-58, 2004. 41. Försti A, Louhelainen J, Söderberg M, Wijkström H, and Hemminki K. Loss of heterozygosity in tumour-adjacent normal tissue of breast and bladder cancer. Eur J Cancer. 37: 1372-1380, 2001. 42. Nowell PC. The clonal evolution of tumor cell populations. Science. 194: 23-28, 1976. 43. Allan JM, Hardie LJ, Briggs JA, Davidson LA, Watson JP, Pearson SB, Muers MF, Wild CP. Genetic alterations in bronchial mucosa and plasma DNA from individuals at high risk of lung cancer. Int J Cancer. 91: 359-365, 2001. 44. Sánchez-Céspedes M, Monzó M, Rosell R, Pifarré A, Calvo R, López-Cabrerizo MP, Astudillo J. Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol. 9: 113-116, 1998. 45. Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res. 5: 2689-2692, 1999. 46. An Q, Liu Y, Gao Y, Huang J, Fong X, Liu L, Zhang D, Zhang J, Cheng S. Deletion of tumor suppressor genes in Chinese non-small cell lung cancer. Cancer Lett. 184: 189-195, 2002. 47. GDB ™ Human Genome Database [database online]. Johns Hopkins University, Baltimore, Maryland, USA. 1990-, updated daily. Available from Internet: URL http://www.gdb.org/. 48. Bando K, Nagai H, Matsumoto S, Koyama M, Kawamura N, Onda M, Emi M. Identification of a 1-cM region of common deletion on 4q35 associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer. 25: 284-289, 1999. 49. Sekido Y, Fong KM, and Minna JD. Molecular genetics of lung cancer. Annu. Rev. Med. 54: 73-87, 2003. 50. Zukerberg LR, Patrick GN, Nikolic M, Humbert S, Wu CL, Lanier LM, Gertler FB, Vidal M, Van Etten RA, and Tsai LH. Cables links cdk5 and c-Abl and facilitates cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron, 26: 633–646, 2000. 51. Wu CL, Kirley SD, Xiao H, Chuang Y, Chung DC, Zukerberg LR. Cables enhances cdk2 tyrosine 15 phosphorylation by Weel, inhibits cell growth, and is lost in many human colon and squamous cancers. Cancer Res 61: 7325- 7332, 2001. 52. Dong Q, Kirley S, Rueda B, Zhao C, Zukerberg LR, Oliva E. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer. Mod Pathol. 16: 863-868, 2003. 53. Tan D, Kirley S, Li Q, Ramnath N, Slocum HK, Brooks JS, Wu CL, Zukerberg LR. Loss of cables protein expression in human non-small cell lung cancer: a tissue microarray study. Hum Pathol. 34: 143-149, 2003. 54. Zukerberg LR, DeBernardo RL, Kirley SD, D'Apuzzo M, Lynch MP, Littell R D, Duska LR, Boring L, Rueda BR. Loss of cables, a cyclin-dependent kinase regulatory protein, is associated with the development of endometrial hyperplasia and endometrial cancer. Cancer Res. 64: 202-8, 2004. 55. Yoshino I, Fukuyama S, Kameyama T, Shikada Y, Oda S, Maehara Y, Sugimachi K. Detection of loss of heterozygosity by high-resolution fluorescent system in non-small cell lung cancer: association of loss of heterozygosity with smoking and tumor progression. Chest. 123: 545-550, 2003. 56. A web site established in 1988 as a national resource for molecular biology information. NCBI (National Center for Biotechnology Information) creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information - all for the better understanding of molecular processes affecting human health and disease. URL http://www.ncbi.nlm.nih.gov. 57. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 56: 265-71, 1995. 58. Rong Y, Wu XF, Chen GM, Zhao M, Wu XX. Microsatellite instability and loss of heterozygosity of human leucocyte antigen class I gene in cervical carcinoma. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 21: 342-346, 2004. 59. Harima Y, Harima K, Sawada S, Tanaka Y, Arita S, Ohnishi T. Loss of heterozygosity on chromosome 6p21.2 as a potential marker for recurrence after radiotherapy of human cervical cancer. Clin Cancer Res. 6: 1079-1085, 2000. 60. Hiraki A, Fujii N, Murakami T, Kiura K, Aoe K, Yamane H, Masuda K, Maeda T, Sugi K, Darzynkiewicz Z, Tanimoto M, Harada M. High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines. Anticancer Res. 24: 1525-1528, 2004. 61. Ozbek N, Birinci A, Karaoglanoglu O, Coban AY, Okumus B, Cakir S, Durupinar B. HLA alleles and lung cancer in a Turkish population. Ann Saudi Med. 24: 106-111, 2004. 62. Hiraki A, Kaneshige T, Kiura K, Ueoka H, Yamane H, Tanaka M, Harada M. Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer. Clin Cancer Res. 5: 933-936, 1999. 63. Theile M, Seitz S, Arnold W, Jandrig B, Frege R, Schlag PM, Haensch W, Guski H, Winzer KJ, Barrett JC, Scherneck S. A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene. 13: 677-685, 1996. 64. Shridhar V, Staub J, Huntley B, Cliby W, Jenkins R, Pass HI, Hartmann L, Smith DI. A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer. Oncogene. 18: 3913-3918, 1999. 65. Abe T, Makino N, Furukawa T, Ouyang H, Kimura M, Yatsuoka T, Yokoyama T, Inoue H, Fukushige S, Hoshi M, Hayashi Y, Sunamura M, Kobari M, Matsuno S, Horii A. Identification of three commonly deleted regions on chromosome arm 6q in human pancreatic cancer. Genes Chromosomes Cancer. 25: 60-64, 1999. 66. Tucci S, Futterweit W, Concepcion ES, Greenberg DA, Villanueva R, Davies TF, Tomer Y. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab. 86: 446-449, 2001. 67. Yanaihara N, Okamoto A, Matsufuji S. A commonly deleted region in ovarian cancer on chromosome 19p13.3, not including the OAZ1 gene. Int J Oncol. 23: 567-575, 2003. 68. Ho WL, Chang JW, Tseng RC, Chen JT, Chen CY, Jou YS, Wang YC. Loss of heterozygosity at loci of candidate tumor suppressor genes in microdissected primary non-small cell lung cancer.Cancer Detect Prev. 26: 343-349, 2002. 69. Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, Espana P, Bonilla F. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat. 57: 237-243, 1999. 70. Rubin MA, Gerstein A, Reid K, Bostwick DG, Cheng L, Parsons R, Papadopoulos N. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph node-negative (pT2-3, N0) prostate cancer. Hum Pathol. 31: 504-508, 2000. 71. Li JY, Zheng HC, Yang L, Xu L, Yang XF, Gao H, Zhang YC, Xin Y. Altered expression of PTEN gene and LOH of its epigenetic microsatellite in gastric carcinoma. Zhonghua Zhong Liu Za Zhi. 26: 389-392, 2004. 72. Dominguez G, Silva J, Silva JM, Garcia JM, Miralles C, Rodriguez O, Jareno E, Provencio M, Espana P, Bonilla F. Clinicopathological characteristics of breast carcinomas with allelic loss in the p73 region. Breast Cancer Res Treat. 63: 17-22, 2000. 73. Chizhikov V, Zborovskaya I, Laktionov K, Delektorskaya V, Polotskii B, Tatosyan A, Gasparian A. Two consistently deleted regions within chromosome 1p32-pter in human non-small cell lung cancer. Mol Carcinog. 30: 151-158, 2001. 74. Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD and Gazdar AF, Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene. 18: 643-650, 1999. 75. Burke L, Khan MA, Freedman AN, Gemma A, Rusin M, Guinee DG, Bennett WP, Caporaso NE, Fleming MV, Travis WD, Colby TV, Trastek V, Pairolero PC, Tazelaar HD, Midthun DE, Liotta LA, Harris CC. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res. 58: 2533-2536, 1998. 76. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti MA, and Sozzi G. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in the cell cycle control. Proc. Natl. Acad. Sci. USA. 96: 8489-8492, 1999. 77. Tomizawa Y, Iijima H, Nomoto T, Iwasaki Y, Otani Y, Tsuchiya S, Saito R, Dobashi K, Nakajima T, Mori M. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer. Lung Cancer. 46: 305-312, 2004. 78. Tzao C, Tsai HY, Chen JT, Chen CY, Wang YC. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer. Eur J Cancer. 40: 2175-2183, 2004. 79. Kondo T, Oue N, Mitani Y, Kuniyasu H, Noguchi T, Kuraoka K, Nakayama H, Yasui W. Loss of heterozygosity and histone hypoacetylation of the PINX1 gene are associated with reduced expression in gastric carcinoma. Oncogene. 24: 157-164, 2005. 80. Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD, Gazdar AF. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA. 273: 1908, 1995. 81. Wistuba II, Behrens C, Virnami AK, Milchgrub S, Syed S, Lam S, Machay B, Minna JD and Gazdar AF, Allelic loses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res. 59: 1973-1979, 1999. 82. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 253: 49-53, 1991. 83. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 342: 705-708, 1989. 84. Jiricny, J. (1998) Replication errors: cha(lle)nging the genome. EMBO J. 17: 6427-6436, 1998. 85. Shin KH, Park JG. Microsatellite instability is associated with genetic alteration but not with low levels of expression of the human mismatch repair proteins hMSH2 and hMLH1. Eur J Cancer. 36: 925-931, 2000. 86. Lim S, Lee HS, Kim HS, Kim YI, Kim WH. Alteration of E-cadherin-mediated adhesion protein is common, but microsatellite instability is uncommon in young age gastric cancers. Histopathology. 42: 128-136, 2003. 87. Zhang JH, Xu M. DNA fragmentation in apoptosis. Cell Res. 10: 205-211, 2000. 88. Tanaka K, Nagaoka S, Takemura T, Arai T, Sawabe M, Takubo K, Sugihara K, Kitagawa M, Hirokawa K. Incidence of apoptosis increases with age in colorectal cancer. Exp Gerontol. 37: 1469-1479, 2002. 89. Roland M, Rudd RM. Somatic mutations in the development of lung cancer. Thorax. 53: 979-983, 1998.
|